Dr. Liu, professor of epidemiology and medicine at Brown University, says: “This protein seems to capture the cumulative effect between the gene and our environment in reflecting a metabolic state of our body, particularly in the liver, ultimately affecting diabetes risk.” Additionally, the research showed that the significant associations of SHBG in women did not vary between ethnic groups. “This is the largest study conducted to date that shows that ethnic-specific differences concerning SHBG levels, if any, are not significant enough to warrant an ethnic specific reference for potential clinical application of this protein for diabetes risk stratification,” says Dr. Atsushi Goto, first author of the study and endocrinologist at the Japanese Diabetes Research Center of the National Center for Global Health and Medicine in Tokyo. SHBG levels ‘should be used for high-risk patients’ Dr. Liu says that it is important to track lifestyle and demographic links with SHBG levels, as they give doctors a point of reference on what SHBG levels could exist in patients. The research could also lead to potential new interventions, as BMI, physical activity, estrogen therapy and coffee intake can all be adjusted.
For the original version including any supplementary images or video, visit http://www.medicalnewstoday.com/articles/266400.php
Joslin Diabetes Center And Clinton Foundation Join For Diabetes Innovation And Year-Round Support For Healthier Communities
Typically triggered by poor control of diabetes and blood pressure , diabetic nephropathy can cause such symptoms as fatigue, headache, nausea, and swelling of the legs. While better control of diabetes and blood pressure is crucial for treatment of diabetic nephropathy, there’s some evidence that certain natural remedies can also help fight this condition. For instance, preliminary research shows that an herb known as shatavari may aid in treatment of diabetic nephropathy. Rich in antioxidants, shatavari has been found to prevent abnormal changes in kidney tissue in animal-based research.
For the original version including any supplementary images or video, visit http://altmedicine.about.com/b/2013/09/23/ayurveda-for-diabetes-defense.htm
Ayurveda for Diabetes Defense
The goals of CHMI are to reduce the prevalence of preventable health outcomes, close health inequity and disparity gaps, and reduce health care costs by improving access to key contributors of health for all people. The Clinton Foundation will co-sponsor and participate in Joslin’s Diabetes Innovation leadership effort, which is capped by the groundbreaking Diabetes Innovation 2013 event taking place on October 3-5 in Washington DC. Diabetes Innovation 2013 is a convening event for all stakeholders in the diabetes community — public and private purchasers, patients, payers, providers, advocates and suppliers — and the organizations will jointly leverage this platform to encourage and support efforts to develop actionable commitments that will help advance the broader strategy to prevent and treat diabetes. “Joslin Diabetes Center is extremely excited to offer our immense knowledge base and proven evidence-based clinical and educational IP and resources to the national CHMI effort,” said John L. Brooks III, President and CEO of Joslin Diabetes Center. “We believe this partnership in conjunction with the Diabetes Innovation effort will really boost local and community efforts to turn back this enormous cost and quality of life burden of diabetes, its comorbidities and related conditions.” Brooks continued, “Since Diabetes Innovation is more than a conference, but is also a ‘call to action,’ the action-oriented approach to change as supported by CHMI is a perfect fit to accomplish our goals.” Beyond the Diabetes Innovation effort, Joslin Diabetes Center and CHMI will work collaboratively to activate systems change and individual behavior change for healthier, more productive and efficient communities by: (1) convening key stakeholders to discuss policy and systems strategy related to diabetes prevention; (2) developing commitments from corporations, public agencies, and non-governmental organizations that are aligned with diabetes prevention; and (3) celebrating companies and organizations that achieve improvements in the arena of diabetes prevention and treatment for preventing related illnesses. “Joslin Diabetes Center is the preeminent academic source of education and clinical care that works for those with or at risk for diabetes,” according to Ginny Ehrlich, CEO of CHMI. “We couldn’t have engaged a better partner than Joslin to solidify our efforts in tackling this chronic and costly disease and its many related conditions and complications”.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/09/18/ma-joslin-diabetes-idUSnPNNE82389+1e0+PRN20130918